Trial
NCT05128773
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Breast International Group; Alliance Foundation Trials, LLC.; European Organisation for Research and Treatment of Cancer - EORTC
Condition
Breast Cancer
Intervention
Amcenestrant
Why stopped
Sponsor decision to prematurely stop the study, not linked to any safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-16